UAE

The primary national regulatory authority for health products in the UAE is the Ministry of Health and Prevention (MOHAP), which oversees registration and market authorization at the federal level. Key governing legislation includes Federal Law No. 4 of 1983 on the Pharmaceutical Profession and its subsequent amendments, alongside Cabinet Resolutions and ministerial decisions that define registration pathways for pharmaceuticals, medical devices, diagnostics, and digital health solutions. At the emirate level, the Dubai Health Authority (DHA) and the Department of Health Abu Dhabi (DoH) exercise parallel regulatory powers within their respective jurisdictions, meaning that products may require additional approvals or notifications to operate across all seven emirates. MOHAP administers a product registration system through its online Sheryan platform, where applicants submit technical dossiers, clinical evidence, and conformity documentation for review prior to market authorization.

Key submission requirements include the appointment of a locally registered pharmaceutical or medical device agent who acts as the authorized representative and holds legal accountability for the product in the UAE market. MOHAP accepts dossiers prepared in accordance with the Common Technical Document (CTD) format for pharmaceuticals, and aligns medical device submissions with standards referencing the Global Medical Device Nomenclature (GMDN) and conformity assessments from recognized bodies such as CE, FDA, or equivalent authorities. For digital health and Software as a Medical Device (SaMD), MOHAP and the emirate-level authorities have issued dedicated guidance frameworks, including the UAE's National Digital Health Strategy and MOHAP's digital health product classification guidelines. Notable recent reforms include the adoption of an expedited registration pathway for products already approved by reference regulatory authorities such as the US FDA, EMA, Health Canada, or TGA, significantly reducing review timelines for such products, as well as increased harmonization efforts under the Gulf Cooperation Council (GCC) Standardization Organization to align registration requirements across member states.

Public procurement of health products in the UAE operates through a combination of federal and emirate-level channels. At the federal level, MOHAP manages procurement for federal health facilities and coordinates with the Federal Authority for Government Human Resources and the Department of Finance on tender processes. Abu Dhabi's health system is organized under the DoH and procured largely through SEHA (Abu Dhabi Health Services Company), which manages the emirate's public hospital network and conducts its own tender and formulary listing processes. In Dubai, the DHA oversees public health facility procurement, while the Northern Emirates rely more directly on MOHAP-coordinated supply chains. Tenders are typically published through the relevant authority's e-procurement portal or through the UAE Government's centralized tendering platforms, and suppliers must hold valid product registrations and local agent agreements to qualify for participation. Framework agreements and long-term supply contracts are common for high-volume consumables, diagnostics, and pharmaceuticals.

The private sector constitutes a substantial share of health product consumption in the UAE, given the high proportion of private hospitals, clinics, and diagnostic laboratories, particularly in Dubai and Abu Dhabi. Private sector procurement is largely decentralized and handled directly between distributors, authorized local agents, and facility procurement departments, governed by insurance formulary requirements set by the respective emirate-level regulatory bodies. The UAE does not typically rely on donor-funded procurement channels such as UNICEF Supply Division, the Global Fund, or Gavi, given its high-income country status, although UAE-based entities such as the Abu Dhabi Fund for Development and local humanitarian organizations may facilitate health product procurement for international aid programs. The UAE government has introduced local manufacturing preference policies as part of its industrial strategy, including incentives under the Operation 300bn advanced industries program, which encourages pharmaceutical and medical device manufacturing within the country and may offer preferential consideration in public tenders for locally produced or locally assembled products.